A systems approach uncovers drivers of the multifocal emergence of an astrocyte state contributing to cognitive decline in Alzheimer's disease

A non-canonical reactive astrocyte state (Ast10) is linked to neuropathologies and cognitive decline in Alzheimer's disease across diverse human brains.

• Why it matters: Understanding the tissue signals and cellular states driving cognitive decline in AD is crucial for developing targeted therapies, as their mechanisms remain unclear.
• What they did: A single-nucleus atlas from 867 brains was analyzed to identify cell-state associations, and ligand-receptor modeling along with validation in mouse and human astrocytes uncovered regulators like PLXNB1, JAM2, and SEMA4D.
• The result: Ast10 markers are pharmacologically modifiable in cerebrospinal fluid, and their reduction correlates with cognitive stabilization, suggesting Ast10 as a potential therapeutic target to mitigate dementia progression.